ReviewNaunyn-Schmiedeberg's archives of pharmacology2006
How valid are animal models to evaluate treatments for pulmonary hypertension?
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 72 citations in OpenAlex.
- A bibliometric study of the most-cited research articles and reviews in Naunyn-Schmiedeberg's Archives of Pharmacology (1969-2024).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeted delivery ofActa pharmaceutica Sinica. B · 2025Article
- Hypoxia modeling techniques: A review.Heliyon · 2023Review
- Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline.Molecular medicine (Cambridge, Mass.) · 2022Article
- Plexiform Lesions in an Experimental Model of Monocrotalin-Induced Pulmonary Arterial Hypertension.Arquivos brasileiros de cardiologia · 2020Article
- Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model.Journal of translational medicine · 2020Article
- Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.Hypertension (Dallas, Tex. : 1979) · 2018Review
- Association between a Single Nucleotide Polymorphism in the 3'-UTR ofDisease markers · 2018Article
- BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.Cellular and molecular life sciences : CMLS · 2017Review
- Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.Anatolian journal of cardiology · 2017Article
- Article
- Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.International journal of clinical and experimental pathology · 2015Article
- Systems approach to the study of stretch and arrhythmias in right ventricular failure induced in rats by monocrotaline.Progress in biophysics and molecular biology · 2014Article
- A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?Pulmonary circulation · 2013Review
- The right ventricle: biologic insights and response to disease: updated.Current cardiology reviews · 2013Review
- MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.American journal of physiology. Heart and circulatory physiology · 2013Article
- Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension.Molecular and cellular biochemistry · 2013Article
- Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension.American journal of physiology. Cell physiology · 2012Article
- Effect of small hairpin RNA targeting endothelin-converting enzyme-1 in monocrotaline-induced pulmonary hypertensive rats.Journal of Korean medical science · 2012Article
- A low mortality model of chronic pulmonary hypertension in sheep.The Journal of surgical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various animal models of pulmonary hypertension (PH) exist, among which injection of monocrotaline (MCT) and exposure to hypoxia are used most frequently. These animal models have not only been used to characterize the pathophysiology of PH and its sequelae such as right ventricular hypertrophy and failure, but also to test novel therapeutic strategies. This manuscript summarizes the available treatment studies in animal models of PH, and compares the findings to those obtained in patients with PH. The analysis shows that all approaches which have proven successful in patients, most notably prostacyclin and its analogs and endothelin receptor antagonists, are also effective in various animal models. However, the opposite it not always true. Therefore, promising results in animals have to be interpreted carefully until confirmed in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.